Vitaros Cream
Vitaros Cream is a prescription medication used to treat Erectile Dysfunction (ED) in men aged 18 and over. Its active ingredient, Alprostadil, is a vasodilator that works by relaxing the smooth muscles and widening the blood vessels in the penis, allowing for increased blood flow to facilitate an erection. Unlike oral tablets, Vitaros is applied directly into the urethra at the tip of the penis. It is a discreet, on-demand treatment that starts working within 5 to 30 minutes and is available in two strengths following a consultation with a healthcare professional.
Complete a short online consultation so our prescriber can confirm the treatment suits you.
The decision to supply the specific treatment and quantity requested will be based on whether our medical team are satisfied that it will be safe, appropriate, and effective.
Or 3 interest-free payments of £20.33 via Klarna
Vitaros Treatment
| Product Name | Vitaros |
| Manufacturer | Ferring GmbH |
| Active Ingredient | Alprostadil |
| Administration | Topical (Urethral Application) |
| Presentation | Cream in single-use AccuDose™ containers |
| Available Strengths | 300 mcg / 4 x Single-use containers |
| Product Type | POM — Prescription Only |
| Starting Price | £60.99 |
| Suitable for pregnancy? | Not for use by women |
| Use with alcohol | Caution advised (may reduce effect) |
| Link to Patient Information Leaflet | Vitaros PIL ↗ |
Vitaros Pricing
| Package type | Price | Availability |
|---|---|---|
| 300 mcg / 4 x Single-use containers | £60.99 | In stock |
Medical Content Manager
Nabeel is a co-founder, and medical content manager of Chemist Doctor. He works closely with our medical team to ensure the information is accurate and up-to-date.
Medical Doctor
Dr. Talal is a GMC registered doctor and medical reviewer at Chemist Doctor. He ensures clinical accuracy and reliability across health content.
Medical Director
Usman is a co-founder, and medical director of Chemist Doctor. He leads the organisation's strategic vision, bridging clinical and operational priorities.
Review Date: 2 Jul 2026
Next Review: 1 Jan 2027
Published on: 19 Nov 2025
Last Updated: 3 Jul 2026